Diabetes

September 26, 2017

Natural product-based therapy for TIIDM: A pharmaceutical mixture encompassing Fucosterol; EGCG; Scopoletin; Cholecalciferol; Celastrol (FESCC) augments the expression of FGF19 and FGF1,   attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIIDM via up regulation of its target gene, 26/September/2017, 9.15 pm

Introduction: What they say A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection […]
September 19, 2017

Molecular therapy for TIIDM and obesity-associated metabolic deficits:  Fluoxetine, an anti-depressant drug, increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 19/August/2017, 11.23 pm

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that […]
September 17, 2017

Natural product-based therapy for TIIDM: Polymethoxyflavonoids, isolated from Black Ginger, augment the expression of FGF19 and FGF1,   attenuate hepatic glucose production, decrease hepatic acetyl CoA content, bring down the levels of plasma ACTH, and corticosterone, augment insulin sensitivity, promote weight loss and alleviate TIIDM via up regulation of their target gene, 18/September/2017, 12.25 am

Introduction: What they say A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection […]
September 16, 2017

Natural product-derived regenerative therapy for reversing diabetes: A pharmaceutical mixture encompassing Luteolin, Apigenin, and Formononetin (LAF) increases the expression of Sox17, Sox2, Pdx-1, and Ngn3, decreases mTOR expression, promotes regeneration of insulin-producing ß cells, increases insulin secretion, promotes glucose homeostasis and reverses T1D and T2D via down regulation of its target gene, 16/September/2017, 11.31 pm

Introduction: What they say A study from the Longevity Institute, School of Gerontology, Department of Biological Sciences, University of Southern California, 3715 McClintock Avenue, Los Angeles, […]